drugset / Trial / NCT00034281
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
Timeline
- Start
- 2002-06
- Primary completion
- 2003-09
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUBRITINIB | Small molecule | 10 mg | Oral |